A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients with Systemic Lupus Erythematosus and Active Cutaneous Lupus Erythematosus

Status: Recruiting

Description:

The main purpose of this study is to gather information about DS-7011a, an investigational drug that may help to treat systemic lupus erythematosus (SLE), including cutaneous lupus erythematosus (CLE). Overall study duration for a participant is expected to be approximately 28 weeks.

I'm interested

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

• Diagnosed with Lupus at least 6 months ago
• active CLE (acute, subacute, and chronic cutaneous lupus), with active skin involvement
• Body mass index (BMI) at least 18 kg/m and body weight at least 45 kg (99lbs.)
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

• history of cancer in the past 2 years
• history of chronic, recurrent (3 or more of the same type of infection in 1 year) or recent serious infection including HIV, viral hepatitis, or shingles

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

CLE, Lupus, SLE, Systemic Lupus Erythematosus

Study Contact: Gretchen Bellefeuille - belle116@umn.edu

Principal Investigator: David Pearson

IRB Number: SITE00002046

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.

A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients with Systemic Lupus Erythematosus and Active Cutaneous Lupus Erythematosus

Email this study information to me

Contact the study team